Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae

被引：16
作者：
Varon, E [1 ]
Gutmann, L [1 ]
机构：
[1] Univ Paris 06, LRMA, F-75270 Paris 6, France
来源：
RESEARCH IN MICROBIOLOGY | 2000年 / 151卷 / 06期
关键词：
Streptococcus pneumoniae; fluoroquinolone; pneumococcus; beta lactams;
D O I：
10.1016/S0923-2508(00)00167-4
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The development of fluoroquinolones (FQs) with enhanced activity against Streptococcus pneumoniae is a potential advance in the treatment of pneumococcal infections, particularly those due to beta-lactam-resistant pneumococci. However, FQ-resistant clinical isolates selected by the older FQs have already been reported, with mutation(s) in both FQ targets conferring cross-resistance to newer FQs. It is likely that recombinational events between topoisomerase genes from related species of streptococci contribute to the spread of FQ resistance in S. pneumoniae. A scenario resembling that of the worldwide spread of resistance to beta lactams should be anticipated. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码：471 / 473
页数：3
相关论文
共 20 条
[1]   Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035
[2]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[3]   DNA gyrase, topoisomerase IV, and the 4-quinolones [J].
Drlica, K ;
Zhao, XL .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+
[4]   Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae [J].
Gill, MJ ;
Brenwald, NP ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) :187-189
[5]   Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci [J].
González, I ;
Georgiou, M ;
Alcaide, F ;
Balas, D ;
Liñares, J ;
De la Campa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2792-2798
[6]   Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong [J].
Ho, PL ;
Que, TL ;
Tsang, DNC ;
Ng, TK ;
Chow, KH ;
Seto, WH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1310-1313
[7]   In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S-mitis [J].
Janoir, C ;
Podglajen, I ;
Kitzis, MD ;
Poyart, C ;
Gutmann, L .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :555-558
[8]   High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].
Janoir, C ;
Zeller, V ;
Kitzis, MD ;
Moreau, NJ ;
Gutmann, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764
[9]   The mechanism of inhibition of topoisomerase IV by quinolone antibacterials [J].
Khodursky, AB ;
Cozzarelli, NR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (42) :27668-27677
[10]   ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].
Munoz, R ;
DelaCampa, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257
12